Background
Insulin was discovered in 1921 by Frederick Banting, Charles Best, and colleagues at the University of Toronto; the first successful therapeutic use in a human patient occurred in January 1922, transforming type 1 diabetes from a rapidly fatal condition to a manageable disease. Early preparations were extracted from bovine and porcine pancreases. Recombinant DNA technology enabled production of human insulin at commercial scale; the first recombinant human insulin (Humulin) was approved by the FDA in 1982. From the 1990s onward, engineered insulin analogs with modified amino acid sequences provided more predictable pharmacokinetics — rapid-acting analogs for meals and long-acting analogs for basal coverage — with delivery innovations including insulin pens, pumps, and integration with continuous glucose monitors further improving flexibility.
Evidence snapshot
Insulin replacement is lifesaving and mandatory in type 1 diabetes. The DCCT demonstrated that intensive insulin therapy reduces microvascular complications (retinopathy, nephropathy, neuropathy) compared with conventional therapy, establishing the foundation for modern glycemic targets while highlighting the tradeoff with hypoglycemia risk.
In type 2 diabetes, insulin improves glycemic control when lifestyle measures and oral or GLP-1-based therapies are insufficient. UKPDS showed that blood-glucose lowering with insulin reduces microvascular complications; effects on long-term macrovascular outcomes vary by context, intensity, and comparator treatment.
Different formulations — rapid-, short-, intermediate-, and long-acting — and delivery methods (multiple daily injections vs. continuous subcutaneous insulin infusion) allow regimens to approximate physiologic insulin secretion. Multiple trials and meta-analyses demonstrate that analog insulins reduce hypoglycemia risk and day-to-day variability compared with older human insulins.
Acute clinical uses are well-supported: IV insulin infusion regimens for DKA and hyperosmolar hyperglycemic state rapidly correct hyperglycemia and ketosis; co-administration of IV insulin and dextrose is a standard short-term treatment for hyperkalemia. Hypoglycemia and weight gain require active monitoring and dose adjustment in all settings.
Administration routes and bioavailability
Subcutaneous injection is the standard route for outpatient basal and bolus dosing; onset and duration differ markedly by formulation (see Variations). Intravenous insulin acts within minutes and is used in DKA, hyperosmolar hyperglycemic state, and critical-care glycemic management. Intramuscular absorption is faster than subcutaneous but is not used in routine diabetes care. Oral insulin is not clinically available because digestive proteases degrade the peptide before absorption; inhaled insulin (Afrezza) is approved as a rapid-acting alternative but has limited adoption. All available clinical insulins bypass the gastrointestinal tract.
Populations studied and special considerations
Clinical evidence spans children, adults, older adults, pregnant individuals with pregestational or gestational diabetes, and hospitalized patients. Insulin is the preferred antihyperglycemic agent in pregnancy due to its established safety profile and lack of placental transfer at standard doses. Older adults generally benefit from relaxed glycemic targets (e.g., HbA1c 7.5–8.5% depending on comorbidities) to reduce hypoglycemia risk. Insulin requirements increase during infection or steroid treatment and may fall sharply during illness with poor oral intake, requiring active monitoring in both directions.
Long-term safety and cardiovascular outcomes
Tight glycemic control with insulin reduces microvascular complications in both type 1 and type 2 diabetes. Evidence on macrovascular outcomes is more nuanced: DCCT/EDIC follow-up showed cardiovascular benefit from earlier intensive control in type 1 diabetes. In longstanding type 2 diabetes with established cardiovascular disease, trials such as ACCORD demonstrated that very intensive glycemic control (HbA1c target <6%) increased all-cause mortality compared with standard control, driven in part by severe hypoglycemia — a finding that led to individualized rather than uniformly tight targets. The ORIGIN trial found no significant increase in cardiovascular events with insulin glargine versus standard care in people with dysglycemia at high cardiovascular risk.
Monitoring and hypoglycemia management
Capillary glucose monitoring or continuous glucose monitoring (CGM) is recommended when initiating or intensifying insulin therapy. Standard hypoglycemia treatment: 15–20 g of fast-acting carbohydrate (glucose tablets, juice), recheck glucose in 15 minutes, repeat if still below target. For severe hypoglycemia with impaired consciousness, glucagon (injectable or intranasal) or IV dextrose is required. Persistent patterns of hypoglycemia (nocturnal, post-exercise, fasting) should prompt regimen review — including basal dose, correction factor, and carbohydrate ratio — rather than simply instructing patients to eat more.
Compound variations
Insulin lispro (rapid-acting analog)
Onset ~10–20 minutes, used for mealtime coverage and correction doses; shorter peak and duration than regular human insulin.
Common use case
Prandial glucose control and flexible dosing around meals.
Dosage note
Administer 0–15 minutes before meals. Dose is individualized using the insulin-to-carbohydrate ratio (500 rule) and correction factor (1800 rule); do not use a fixed dose without individualization.
Insulin aspart (rapid-acting analog)
Similar pharmacokinetics to lispro — rapid onset, short duration — suitable for mealtime use and insulin pump infusion.
Common use case
Mealtime boluses and continuous subcutaneous insulin infusion (pump) therapy.
Dosage note
Typically administered immediately before or within 20 minutes of starting a meal. Dose calculated using carbohydrate counting and individualized correction factors.
NPH insulin (intermediate-acting)
Historically common basal insulin with a pronounced peak several hours after injection; associated with more day-to-day variability and nocturnal hypoglycemia risk than long-acting analogs.
Common use case
Patients without access to analog insulins or those using twice-daily mixed regimens.
Dosage note
Often dosed twice daily. Inject 30 minutes before meals when used as part of mixed regimens. Resuspend (roll gently) before each dose.
Insulin glargine (long-acting analog)
Long-acting basal insulin providing relatively flat 24-hour coverage; duration depends on formulation (U-100 vs. U-300) and individual pharmacokinetics.
Common use case
Once-daily basal control with lower nocturnal hypoglycemia risk compared with NPH in clinical trials.
Dosage note
Start at 10 units nightly or 0.1–0.2 units/kg; titrate based on fasting glucose readings. Do not mix with other insulins in the same syringe.
Dosage and best practices
Dosage principles
- Typical total daily insulin dose for new-onset type 1 diabetes: approximately 0.4–1.0 units/kg/day, divided into basal and prandial components (basal ~40–50% of total daily dose).
- Starting basal insulin for adults with type 2 diabetes: 10 units once daily or 0.1–0.2 units/kg/day, titrated against fasting glucose over days to weeks per ADA practice guidance.
- Insulin-to-carbohydrate ratio is approximated by the '500 rule' (500 ÷ total daily dose = grams of carbohydrate covered by 1 unit of rapid-acting insulin); correction factor is approximated by the '1800 rule' (1800 ÷ total daily dose = mg/dL glucose reduction per 1 unit). Both rules provide starting estimates that must be individualized.
- DKA IV insulin in adults: 0.1 units/kg IV bolus followed by 0.1 units/kg/hour infusion; alternatively, 0.14 units/kg/hour without a bolus. Adjust for glucose response and transition to subcutaneous insulin when ketosis resolves and the patient is tolerating oral intake.
Best practices
- Match insulin type to clinical need: rapid-acting analogs for mealtime boluses, long-acting basal analogs for background control. Adjust timing relative to meals and activity level.
- Rotate subcutaneous injection or pump sites to reduce lipodystrophy. Store unopened vials and cartridges refrigerated; in-use pens can be kept at room temperature per manufacturer instructions (typically up to 28–30 days).
- Monitor capillary glucose frequently when initiating or changing regimens. Educate patients on hypoglycemia recognition, the 15-15 rule for treatment (15 g fast-acting carbohydrate, recheck in 15 minutes), and glucagon use for severe events.
- Adjust dosing around illness, exercise, alcohol, and corticosteroid use. Inpatient and perioperative insulin strategies differ meaningfully from outpatient regimens and benefit from protocolized approaches.
Literature and references
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
N Engl J Med • 1993
The DCCT demonstrated that intensive insulin therapy in type 1 diabetes substantially reduced microvascular complications compared with conventional therapy, establishing the evidence base for tight glycemic control.
Effect of intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet • 1998
UKPDS showed that blood-glucose lowering with insulin or sulfonylureas reduced microvascular complications in newly diagnosed type 2 diabetes, informing long-term glycemic targets.
Basal insulin and cardiovascular and other outcomes in dysglycemia
The New England journal of medicine • 2012
Randomized trial in 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance or type 2 diabetes comparing insulin glargine with standard care on cardiovascular outcomes.
Hyperglycemic crises in adult patients with diabetes
Diabetes care • 2009
Effects of intensive glucose lowering in type 2 diabetes (ACCORD).
N Engl J Med • 2008
ACCORD found that targeting HbA1c below 6% increased all-cause mortality compared with standard control in patients with longstanding type 2 diabetes and high cardiovascular risk, leading to individualized rather than uniformly intensive glycemic targets.
Common questions
Is insulin a dietary supplement I can take without a prescription?
No. Insulin is a prescription medication and regulated biologic. It requires medical assessment, individualized dosing, and monitoring because of serious hypoglycemia risk. In the United States, some OTC insulins (NPH, regular) are available at pharmacies in certain states, but use without medical guidance is not appropriate for most patients.
Can insulin be taken orally or as a pill?
No. Digestive enzymes break down the insulin peptide before it can be absorbed; standard clinical insulins must be injected subcutaneously or given intravenously. An inhaled rapid-acting insulin (Afrezza) is FDA-approved but not widely used. Oral insulin delivery systems remain an active research area without approved products for routine care.
Will starting insulin cause weight gain?
Weight gain commonly occurs after initiating or intensifying insulin because improved glycemic control reduces glucose loss in the urine and insulin promotes anabolic processes. The magnitude varies by regimen, dose, and diet. Structured meal planning and physical activity can help limit weight gain.
How quickly do different insulin formulations work?
Rapid-acting analogs (lispro, aspart, glulisine) begin acting within 10–20 minutes, peak at 1–2 hours, and last 3–5 hours. Regular (short-acting) insulin begins working in 30–60 minutes and peaks at 2–4 hours. NPH (intermediate-acting) peaks at 4–12 hours. Long-acting analogs (glargine, detemir, degludec) provide relatively flat basal coverage lasting 18–42 hours depending on the formulation and dose.
How is insulin used in emergencies like DKA or hyperkalemia?
In DKA, IV insulin infusion lowers glucose and suppresses ketogenesis; standard adult regimens use 0.1 units/kg IV bolus then 0.1 units/kg/hour, or 0.14 units/kg/hour without a bolus, adjusted by protocol. For acute hyperkalemia, 10 units IV regular insulin co-administered with 25–50 g dextrose shifts potassium intracellularly, lowering serum potassium within 15–60 minutes; the effect is temporary and must be followed by definitive treatment.